Melatonin may serve as a potential therapeutic option on its own, or in conjunction with 5-FU, in the treatment of patients with advanced or chemoresistant CRC.Melatonin inhibits the growth of 5-FU resistant colorectal cancer (CRC) cells through upregulation of miR-215-5p and a concomitant downregulation of TYMS.
The level of miR-215-3p was correlated with the 5-Fu sensibility of colorectal cancer cell and the alteration of miR-215-3p affected the sensibility of colorectal cancer cells toward 5-Fu.
Our study highlighted for the first time that miR-215 could function as a potential predictive marker for relapse following radical surgery of colorectal cancer, and the possible correlation between miR-215 and 5-fluorouracil-containing adjuvant chemotherapy would be validated in the future.